Madrid, Spain and Heidelberg, Germany, October 27 th , 2015 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it will be presenting at the BIO-Europe 2015 International Partnering Conference being held November 2-4 in Munich, Germany.
Pilar de la Huerta, CEO and CFO of SYGNIS will present at the conference in the “Enabling Technologies” track. The presentation will be held on November 4, at 11:30 am CET in Room 12, Level 1 .
BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma, and finance along with the most exciting emerging companies. It is regarded as a “must attend” event for the biotech industry.
A profile of SYGNIS is available on the partnering360(R) website, the network for dealmakers in the life sciences industry. To schedule a meeting with SYGNIS delegates at this event, please e-mail us at: contact@mc-services.eu.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
SYGNIS, headquartered in Germany and Spain, specializes on the development and commercialization of innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio addressing key challenges in the fast growing fields of molecular biology and next generation sequencing applications. Key products include the TruePrime(TM) product line and SensiPhi (R) , licensed to an industry leading partner, for whole genome DNA amplification and sequencing as well as the SunScript(TM) Reverse Transcriptase product family to convert genetic information from RNA molecules back to DNA. SYGNIS AG is listed at the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).
### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.
Help employers find you! Check out all the jobs and post your resume.
